Eupraxia Pharmaceuticals (TSE:EPRX) has released an update.
Eupraxia Pharmaceuticals has announced the expansion of its RESOLVE trial for EP-104GI, a treatment for eosinophilic esophagitis, due to promising early results and safety data. The trial will now include higher doses and a longer follow-up period of up to 52 weeks, signaling a move towards a potential registration trial for the therapy. The expansion, approved by regulators in Australia and Canada, aims to provide a potentially efficacious and safe annual treatment for EoE sufferers.
For further insights into TSE:EPRX stock, check out TipRanks’ Stock Analysis page.
